Preclinical studies have demonstrated the enhanced in vitro efficacy of KIR/KIR-ligand mismatching against melanoma and renal cell carcinoma (RCC) cells [28]. The gene discussed is KIR3DL1; the disease is hereditary clear cell renal cell carcinoma.